R 2 CHADS 2 score was computed according to Piccini et al, 10 where R stands for renal impairment (electronically calculated estimated glomerular filtration rate [eGFR] <60 ml/min/1.73 m 2 ) and 2 points are given for an eGFR of less than 60 ml/min/1.73 m 2 . The CHA 2 DS 2 VASc-AFR is an original score, developed and tested in the present study, and includes the type of AF (1 point for persistent AF) and renal status (1 point for eGFR <60 ml/min/1.73 m 2 according to Roldan et al).
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Laboratory data Blood samples were collected on admission. In all patients, serum creatinine levels were measured. Kidney function was assessed using eGFR calculated with the Modification of Diet in Renal Disease formula. Renal impairment was defined as an eGFR of less than 60 ml/min/1.73 m 2 .
Echocardiography All patients underwent TEE within 48 hours before the ablation procedure. TEE was performed according to the standard practice guidelines using a commercially available equipment (Vivid 9, GE Vingmed Ultrasound, Horten, Norway, and Vivid S6, GE Healthcare, Israel) with 6T and 6Tc multiplane TEE probes (GE Vingmed Ultrasound). 12,13 Pharyngeal anesthesia was performed with lidocaine spray. Sedation with intravenous midazolam was needed in some patients. The left atrial (LA) and LAA cavities were examined for the presence of a thrombus or spontaneous echocontrast by experienced echocardiographers. Special attention was paid to ensure that the entire LA and LAA were visualized. The LAA emptying velocity was recorded by placing the pulse-wave Doppler gate within 1 cm of the LAA orifice, and emptying velocity of less than 0.4 m/s was considered as decreased. The LA thrombus was defined as an independently mobile round, oval, or irregularly shaped echo-dense structure distinct from the surrounding endocardium or pectinate muscles and detected in more than 1 imaging plane. Dense contrast was defined as dynamic "smoke-like" signal with the characteristic swirling motion, or a dynamic gelatinous, precipitous echo density, without a discrete mass, present throughout the cardiac cycle with appropriate gain settings to distinguish the spontaneous echo contrast from echoes due to excessive gain. Patients with a definite LAA thrombus and with dense contrast with a strong suspicion of a thrombus were classified as the "LAA thrombus" group. In this group, ablation was postponed and a new anticoagulant regimen was initiated.
Statistical analysis
The results were presented as mean ± 1 standard deviation or numbers and percentages. Differences between patients with or without the LAA thrombus were examined using the t test for numerical variables or the χ 2 or Fisher test for qualitative variables. A univariate analysis was performed using odds ratios and 95% confidence intervals (CIs). To assess which parameter was independently associated with the Catheter ablation for AF has become a well--established method of treatment with high success rates when compared with antiarrhythmic drugs. 2, 6 It is mandatory to exclude the presence of a thrombus in the LAA before the procedure. For this purpose, transesophageal echocardiography (TEE) has been used as the gold standard. 2 However, there is no consensus as to whether all patients scheduled for AF ablation should routinely undergo TEE, which is an invasive procedure, carries a risk of complications, is relatively expensive, and can extend the length of hospital stay. 7 This question is especially relevant in patients with a very low risk of thromboembolic events.
The aim of the present study was to assess the predisposing factors for LAA thrombus formation, including those not incorporated in the CHA 2 DS 2 VASc score, in consecutive patients scheduled for AF ablation in our center. We also aimed to establish the necessity for preprocedural TEE and to answer the question whether there are patients in whom this examination could be safely omitted based on the thromboembolic risk calculation.
PATIENTS AND METHODS Study population
The study group consisted of 161 consecutive patients scheduled for AF ablation from January 2012 to March 2014 in our center. All demographic, clinical, laboratory, and TEE data, as well as information on medications, were retrieved from medical records. We performed a retrospective analysis of prospectively collected data. The anticoagulant therapy before ablation was based on the current guidelines and all patients with a CHA 2 DS 2 VASc score of 2 or higher were treated with oral anticoagulants. The decision to administer preablation anticoagulation in patients with a CHA 2 DS 2 VASc score of 0 or 1 was left to the discretion of attending physicians.
Definitions Patients with hypertension were defined as subjects currently using antihypertensive medication, and those with diabetes-as subjects currently using hypoglycemic agents. Chronic heart failure (CHF) was defined as the presence of signs and symptoms of either right or left ventricular failure or both, confirmed by noninvasive or invasive measurements demonstrating objective evidence of cardiac dysfunction.
8 Vascular disease was defined as the presence of at least one of the following: previous myocardial infarction, angina pectoris, percutaneous coronary intervention or coronary artery bypass surgery, intermittent claudication, previous surgery or percutaneous intervention on the abdominal aorta or the lower extremity vessels, abdominal or thoracic surgery, or arterial and venous thrombosis.
8 Paroxysmal AF was defined as recurrent episodes of AF lasting less than 7 days.
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Persistent AF was defined as episodes of AF lasting longer than 7 days.
The CHADS 2 and CHA 2 DS 2 VASc scores were calculated according to standard definitions. The patients with the thrombus were significantly older and significantly more often had persistent AF, diabetes, renal impairment, lower LAA emptying velocity, and higher thromboembolic risk scores (TABLE 1) .
Of the risk factors that compose the CHA 2 DS 2 VASc score, only diabetes and age of 65 years or older were predictors of the LAA thrombus in the univariate analysis. Among other clinical factors, persistent AF and eGFR of less than 60 ml/min/1.73 m 2 were also predictors of the LAA thrombus in the univariate analysis (TABLE 2).
The multivariate logistic regression analysis showed that only persistent AF and eGFR of less than 60 ml/min/1.73 m 2 were independent predictors of the LAA thrombus (TABLE 3) .
Individual clinical, demographic, and echocardiographic parameters of patients from the LAA--thrombus group are shown in TABLE 4. FIGURE 1 shows the ROC curves for various combinations of CHA 2 DS 2 VASc and AF type and renal function, with the corresponding values of the AUC. The ROC curves showed that the CHA 2 DS 2 VASc score alone or in combination with AF type or renal function (or both) performed well in the identification of patients from the LAA-thrombus group. The greatest AUC (0.845) was achieved for the CHA 2 DS 2 VASc-AFR score; however, the difference between the AUC for the CHA 2 DS 2 VASc-AFR (the greatest AUC) and the AUC for the CHA 2 DS 2 VASc (the lowest AUC) did not reach statistical significance (difference between the areas, 0.0495; standard error, 0.0265; 95% CI, 0.00245-0.101; z statistics, 1.868; P = 0.0618).
LAA thrombus, a multivariate logistic regression analysis was performed (with the backward likelihood ratio method and P for stepwise removal >0.10). The Hosmer-Lemeshow test was used to assess the goodness of fit of the model. The receiver operator characteristic (ROC) curves were constructed and the area under the curve (AUC) was calculated to compare the sensitivity and specificity of different scores in the identification of patients with or without the LAA thrombus. The pairwise comparison of ROC curves (using the De Long method) was performed using z statistics. A P value of less than 0.05 was considered significant.
RESULTS
Of 161 patients scheduled for AF ablation, 10 patients were excluded from the current analysis. In 8 patients, TEE was not performed (2 patients did not swallow the probe; in 5 patients, the TEE was unavailable at the time of ablation; and 1 patient had esophageal stricture), and in the remaining 2 patients, LAA was not properly visualized. Thus, the analyzed study group consisted of 151 patients (107 men; mean age, 57 ±10 years). Detailed characteristics of the study group are presented in TABLE 1.
The LAA thrombus was detected in 10 patients, and dense echo contrast with high suspicion of thrombus-in 5 patients. Thus, the LAA-thrombus group consisted of 15 patients (10% of the studied population). In the remaining 136 patients, the LAA cavity was clear (123 patients) or only moderate echo contrast without suspicion of a thrombus was detected (13 patients). Compared with patients without the thrombus, vitamin K antagonists), missing doses in the case of non-vitamin K oral anticoagulants, predisposing anatomical factors such as LAA morphology, or undetected prothrombotic state in a small group of patients. Another reason may be falsepositive results of TEE. It has been shown that intracardiac echocardiography may exclude a thrombus in some patients with positive TEE results; however, the opposite can also occur. 17 Nevertheless, TEE remains the gold standard for the detection of LAA and LA thrombus and the decision whether it is safe to proceed with AF ablation. In our study, TEE allowed to identify the presence of a definite LAA thrombus in 6.6% of the patients and a high probability of a thrombus based on dense echo contrast in 10% of the patients, which is in line with literature data. As expected, we found several significant differences between patients with or without an LAA thrombus in our study. These included well--established factors such as more advanced age, diabetes, and decreased LAA emptying velocity; however, we found 2 factors not included in the CHA 2 DS 2 VASc score that occurred to be independent predictors of the LAA thrombus, namely, persistent AF and renal impairment.
18,19 These 2 factors have been shown to independently increase thromboembolic risk in patients with AF, although in different patient populations than our cohort.
3,5,20,21
Although the AF type is not included in the risk scores, numerous studies have shown that persistent AF carries a higher risk of stroke than paroxysmal AF.
5, 22 The minimum duration of AF that increases the risk of stroke has not been established; however, in the ASSERT study, as short as >6-minute episodes of AF were associated with an increased risk of stroke. 22 The mechanisms by higher when using the CHA 2 DS 2 VASc-AFR than when using the CHA 2 DS 2 VASc score.
DISCUSSION
The present study showed that in patients scheduled for AF ablation a thrombus or dense echo contrast in the LAA (which precludes AF ablation) may be observed in up to 10% of patients despite routine and effectively managed anticoagulation. In addition, the study showed that the absence of an LAA thrombus may be predicted by calculating the thromboembolic risk score. Finally, by adding 2 variables such as persistent AF and renal impairment to the standard CHA 2 DS-2 VASc score, a marginal improvement in the identification of patients who may not require preprocedural TEE is obtained. The LAA thrombus may be detected in a small but clinically significant proportion of patients with AF despite routine anticoagulation. The incidence of the thrombus varies widely in the available studies and ranges from 1.5%-2.0% to 7%. 14-16 This may be due to several reasons such as inadequate doses of anticoagulants (especially heart disease. However, 1 study showed that in unselected patients scheduled for cardioversion or catheter ablation as many as 11% of the subjects with an LAA thrombus had a CHA 2 DS 2 VASc score of 0 or 1.
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Our study showed that patients with a CHA 2 DS-2 VASc score of 0 or a CHA 2 DS 2 VASc-AFR score of 0 or 1 had no LAA thrombus. Much larger prospective studies are needed to assess whether this criterion may be introduced into clinical practice. The CHA 2 DS 2 VASc-AFR score only slightly improved the identification of patients with almost no risk of a thrombus. The reason why the type of AF and renal function only marginally improved thromboembolic risk stratification may be explained by the fact that both parameters may reflect cardiovascular impairment already expressed by the components of the CHA 2 DS 2 VASc score, and, therefore, there is little new information on future risk.
Patients scheduled for AF ablation often routinely undergo other imaging tests capable of detecting an LAA thrombus such as computed tomography, cardiac magnetic resonance, or intracardiac echocardiography. This may be another reason why a no-TEE approach could find its way into clinical practice in the very near future. It may be speculated that adding a thromboembolic risk score including AF type and renal function to the results of new imaging tests would improve differentiation between patients with an LAA thrombus and those with a clear LAA; however, this needs to be examined in prospective studies.
Limitations Owing to the small size of the study group, all our findings are hypothesis-generating. The retrospective nature of the study also precludes firm conclusions; however, all data were collected prospectively at the time of hospitalization for ablation and TEE.
Patients with a definite LAA thrombus and patients with dense echo contrast and hence a strong suspicion of a thrombus were classified as the LAA-thrombus group because, in such patients, ablation is usually postponed. On the other hand, in patients with minor or even moderate echo contrast but without the suspicion of a thrombus, ablation can be safely performed. It has been shown that very dense echo contrast is associated with an increased risk of thromboembolism.
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Although TEE was performed and analyzed by experienced echocardiographers, there is always a possibility of misinterpretation. TEE has been shown to provide both false negative and positive results; however, it still remains the gold standard for the detection of an LAA thrombus.
The eGFR was calculated using the Modification of Diet in Renal Disease formula, which has some limitations. We used only 1 cut-off value for eGFR (<60 ml/min/1.73 m 2 ), and the vast majority of our patients had normal or only slightly decreased eGFR (only 1 patient had an eGFR of less than 30 ml/min/1.73 m 2 ) Thus, our results may which permanent AF carries a higher thromboembolic risk than paroxysmal AF may be multifactorial and include longer periods of LAA/LA stunning, changes in the left atrial wall structure (especially in patients with a long history of persistent AF) or other cardiovascular abnormalities promoting thromboembolism, which are more common in patients with persistent AF.
Renal impairment has been consistently shown to increase thromboembolic risk, including stroke, but the additive value of this parameter in risk stratification scores is debatable. 3 Banerjee et al 23 in a large real-world cohort of patients with nonvalvular AF showed that renal dysfunction was not independently associated with thromboembolic risk and did not improve the predictive power of CHADS 2 and CHA 2 DS 2 VASc scores. 23 However, the population in that study was different from our patients scheduled for AF ablation (more advanced age, more patients with chronic kidney disease, and higher proportion of persistent AF). Also Kornej et al 24 and Chao et al 4 studied patients after AF ablation and suggested that the inclusion of renal function in the risk stratification scores adds little to the existing scores. More positive results were obtained by the ATRIA investigators who showed that adding proteinuria, eGFR of less than 30 ml/min/1.73 m 2 , or endstage renal disease significantly improved thromboembolic risk stratification. 21 Finally, the most recent meta-analysis showed that renal impairment is an independent risk factor for thromboembolic events (relative risk of 1.62) and postulated that it should be added to the existing risk scores. 25 Thus, it may be speculated that in some subgroups of patients with AF adding renal function to the existing risk scores may improve the identification of patients at increased risk of stroke. In addition, as a cardiovascular risk factor, renal impairment improves risk stratification based on the CHA 2 DS 2 VASc scale not only in patients with AF but also in other conditions such as acute coronary syndrome. 26 Out of other parameters examined in our study, the history of stroke-a very potent thromboembolic risk factor-did not show a significant difference between patients with or without the LAA thrombus. This may be explained by a low prevalence of these complications in our population. In general, the thromboembolic risk of our patients was quite low (mean CHA 2 DS 2 VASc, 1.54 ±1.38), as is often observed in patients who are offered AF ablation. 27 The question of whether some patients may not require preprocedural TEE because the risk of an LAA thrombus is very low still remains unanswered. Data from literature are conflicting. Puwananat et al 14 suggested that in patients with a CHADS 2 of 0 who have paroxysmal AF and are treated with anticoagulants, preprocedural TEE may be omitted. Our findings are also similar to those of Calco et al 15 who suggested that preprocedural TEE may be omitted in patients who have paroxysmal AF and no LA dilation or structural not be applicable to patients with more severe renal impairment than those in our study.
Although patients taking non-vitamin K oral anticoagulants were instructed to use a drug according to a prescribed schedule, it is possible that some patients might not have fully complied, which might have predisposed them to the formation of an LAA thrombus. However, with these new agents, it is difficult to assess adherence because there are no routine blood tests assessing the anticoagulation status. 28 Also patients treated with vitamin K antagonists might have had periods of ineffective anticoagulation. Although they were instructed to keep an international normalized ratio between 2.0 and 3.0, it is well known that in clinical practice, time in the therapeutic range rarely exceeds 60%. 29 Another limitation of our study is the lack of LA dimensions in predicting models. This was due to the fact that preprocedural transthoracic echocardiography was performed at various time intervals before ablation and usually in other centers; therefore, it was difficult to fully rely on the LA diameter measurements.
In conclusion, the present study showed that patients scheduled for AF ablation quite often have an LAA thrombus despite adequate anticoagulation. Thromboembolic risk stratification using the CHA 2 DS 2 VASc score, with the addition of data on the type of AF and renal function, may accurately identify low-risk patients who do not require preprocedural TEE; however, this has to be tested in larger prospective trials.
